Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept versus placebo in adults with IgA nephropathy
NL-OMON59667Phase 3Active, not recruiting
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Povetacicept with Placebo (2 arms). Primary endpoints: Change from baseline in 24-hour urine protein to creatinine ratio at Week 36 and Total eGFR slope through Week 104. Started Dec 2024; status: active, not recruiting.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON59667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59667.